Incyte Corp (INCY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 99

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Incyte Corp, Medical Devices Deals, 2011 to YTD 2017 11
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 14
Partnerships 15
AstraZeneca and MedImmune Expands Agreement with Incyte 15
Bristol-Myers Squibb and Incyte Enter into Agreement 16
Incyte Enters into Research Agreement with Abramson Cancer Center 17
Incyte Enters into Distribution Agreement with GENESIS Pharma 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Incyte Enters into Agreement with AstraZeneca 20
Incyte Extends Partnership with Merck 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Licensing Agreements 23
Incyte Enters into Licensing Agreement with MacroGenics 23
Incyte Enters into Licensing Agreement with Calithera Biosciences 24
Incyte Enters into Licensing Agreement with Merus 26
Incyte Amends Licensing Agreement with ARIAD Pharma 28
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 29
Incyte Amends Licensing Agreement with Agenus 30
Equity Offering 32
Incyte Raises USD650 Million in Public Offering of Shares 32
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 34
Agenus Raises USD35 Million in Private Placement of Common Stock 36
Debt Offering 38
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 38
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 40
Acquisition 42
Gilead Sciences May Acquire Incyte 42
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 43
Incyte Corp - Key Competitors 45
Incyte Corp - Key Employees 46
Incyte Corp - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 48
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 50
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 52
Nov 01, 2016: Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs 55
Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs 57
May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs 60
Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs 62
Corporate Communications 64
Oct 30, 2017: Incyte Names New Member to Its Board of Directors 64
Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 65
Product News 66
11/30/2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors 66
09/27/2016: NCCN Guidelines Recommend Jakafi (ruxolitinib) for the Treatment of Myelofibrosis 67
06/23/2016: FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) 68
04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 69
04/18/2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 70
04/18/2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 71
03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72
03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 73
01/21/2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 74
Jan 11, 2016: Incyte Presents Significant Progress in its Development Portfolio 75
Product Approvals 77
Jul 25, 2016: Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint 77
Feb 18, 2016: Health Canada approves PrJakavi (ruxolitinib) for polycythemia vera, a chronic blood cancer 78
Clinical Trials 79
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 79
Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 80
Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 81
Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 82
Mar 28, 2017: Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 83
Dec 04, 2016: Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib) 84
Nov 11, 2016: Calithera Biosciences Announces Presentation on CB-1158 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 85
Sep 28, 2016: Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda (Pembrolizumab) 86
Sep 15, 2016: Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase 87
Sep 07, 2016: Calithera announces poster presentation on CB-1158 preclinical results at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 88
Jul 19, 2016: Updated Data for Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016 89
Jun 22, 2016: Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study 90
Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera 91
Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis 92
May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings 93
Apr 18, 2016: Calithera Biosciences Announces Preclinical Presentation of CB-1158 at the American Association for Cancer Research Annual Meeting 2016 95
Jan 27, 2016: Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP 96
Jan 22, 2016: Calithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia 97
Other Significant Developments 98
Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99

List of Tables
Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Incyte Corp, Deals By Therapy Area, 2011 to YTD 2017 10
Incyte Corp, Medical Devices Deals, 2011 to YTD 2017 11
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 14
AstraZeneca and MedImmune Expands Agreement with Incyte 15
Bristol-Myers Squibb and Incyte Enter into Agreement 16
Incyte Enters into Research Agreement with Abramson Cancer Center 17
Incyte Enters into Distribution Agreement with GENESIS Pharma 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Incyte Enters into Agreement with AstraZeneca 20
Incyte Extends Partnership with Merck 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Incyte Enters into Licensing Agreement with MacroGenics 23
Incyte Enters into Licensing Agreement with Calithera Biosciences 24
Incyte Enters into Licensing Agreement with Merus 26
Incyte Amends Licensing Agreement with ARIAD Pharma 28
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 29
Incyte Amends Licensing Agreement with Agenus 30
Incyte Raises USD650 Million in Public Offering of Shares 32
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 34
Agenus Raises USD35 Million in Private Placement of Common Stock 36
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 38
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 40
Gilead Sciences May Acquire Incyte 42
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 43
Incyte Corp, Key Competitors 45
Incyte Corp, Key Employees 46
Incyte Corp, Subsidiaries 47

List of Figures
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Incyte Corp, Medical Devices Deals, 2011 to YTD 2017 11

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Incyte Corp (INCY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027